As the biggest selling drug of all time begins to be hit by biosimilar competition, Ben Hargreaves asks whether biosimilars adoption could be about to take-off in the US.
Hailed as a breakthrough after many years without new treatments for Alzheimer’s disease, a new generation of therapies for the condition have not been welcomed by payers.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
